ESTROSTEP FE Drug Patent Profile

When do Estrostep Fe patents expire, and when can generic versions of Estrostep Fe launch?

Estrostep Fe is a drug marketed by Apil and is included in one NDA.

The generic ingredient in ESTROSTEP FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for ESTROSTEP FE

US Patents:	0
Applicants:	1
NDAs:	1
Drug Prices:	Drug price information for ESTROSTEP FE
What excipients (inactive ingredients) are in ESTROSTEP FE?	ESTROSTEP FE excipients list
DailyMed Link:	ESTROSTEP FE at DailyMed

See drug prices for ESTROSTEP FE

US Patents and Regulatory Information for ESTROSTEP FE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apil	ESTROSTEP FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-28	020130-002	Oct 9, 1996		DISCN	Yes	No

Expired US Patents for ESTROSTEP FE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apil	ESTROSTEP FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-28	020130-002	Oct 9, 1996	4,962,098
Apil	ESTROSTEP FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-28	020130-002	Oct 9, 1996	5,010,070

International Patents for ESTROSTEP FE

See the table below for patents covering ESTROSTEP FE around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	9203142	CONTRACEPTIVOS DE ESTROGENOS TITULADOS.

Supplementary Protection Certificates for ESTROSTEP FE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
0398460	C300221	Netherlands		PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
1214076	C01214076/01	Switzerland		PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
1380301	CA 2009 00017	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629

ESTROSTEP FE market dynamics and financial trajectory: sales drivers, exclusivity gates, competitive pressure, and revenue outlook

Last updated: July 23, 2026

What is Estrostep FE and where does it sit in the contraceptive market?

Estrostep FE (norethindrone acetate and ethinyl estradiol tablets; ferrous fumarate) is an oral combined hormonal contraceptive (CHC) with a 21-day active regimen plus iron (placebo) days. CHCs compete primarily on formulary access, price, patient adherence (including regimen simplicity and bleeding control), and payer preference.

Market structure

• Primary demand engine: Commercial and government-insured contraception use tied to member growth, persistence, and adherence.
• Second-order drivers: Plan formulary design (preferred tier placement), step therapy, pharmacy benefit manager (PBM) contracting, and copay dynamics.
• Brand economics: CHCs often run on long-tail brand revenue through multiple generic entrants, with financials increasingly determined by net pricing and formulary position rather than sustained demand expansion.

How do market dynamics impact Estrostep FE revenue year over year?

Revenue volatility in CHCs is driven by net pricing and formulary loss, not gross unit growth. For Estrostep FE, the key dynamics are:

• Genericization pressure: Once branded CHCs face generic equivalents or AB-rated alternatives, brand net price erodes and unit share shifts to lower-cost options through pharmacy benefit design.
• Payer churn and plan switching: High turnover among commercial formularies after PBM renegotiations can cause step-down placement to non-preferred tiers.
• Therapy switching within class: Many CHCs are substitutable at the class level, so prescriber switching is frequent when incentives change.

What is the competitive landscape for Estrostep FE versus other oral contraceptives?

Competition is dense. Estrostep FE competes across:

• Same-class CHCs with similar active ingredient profiles (norethindrone-based and other progestins).
• Therapeutic substitutability: Even when formulations differ, payer incentives push patients to the lowest net-cost equivalent.
• Product-form rivalry: Extended-cycle regimens and branded “bleeding control” narratives often outperform older 21/7 or 24/4 patterns in select channels, forcing older brands to rely on contracting strength.

Featured snippet takeaway: Estrostep FE’s competitive positioning is determined less by clinical differentiation and more by formulary placement versus AB-rated generic or preferred CHC options.

How does Estrostep FE compare with other norethindrone acetate/ethinyl estradiol options?

Where multiple CHCs share AB-equivalence on actives or are treated as therapeutic substitutes, the brand’s financial trajectory is typically:

• High early pricing power
• Midlife contraction as generics spread
• Late-stage dependence on niche formularies, restricted coverage dynamics, and patient persistence

How do exclusivity and patent cliffs shape Estrostep FE’s financial trajectory?

Estrostep FE’s long-run brand performance is constrained by generic entry risk. In oral contraceptives, brand survival often reflects:

• Residual exclusivity on specific strengths, dosage forms, or packs
• Patent coverage around formulation or methods of use (when applicable)
• Negotiated market access after generics launch

Revenue gates

• Market exclusivity: Any remaining regulatory exclusivity and patent coverage limits generic entry timing.
• Patent expiry and litigation: Patent expiration is a predictable calendar risk. Settlements can delay generic launch, shifting revenue between years rather than preventing erosion.

Featured snippet takeaway: In CHCs, exclusivity and patents usually determine “when” revenue declines, not “whether” net pricing erodes after generic penetration.

What is the Orange Book status of Estrostep FE, and which patents protect it?

No Orange Book status content is provided here. A complete, accurate patent-and-Orange Book mapping requires drug-specific FDA listing and patent number extraction, which is not available in the provided context.

When does Estrostep FE lose exclusivity, and what launch scenarios matter for generics?

No specific exclusivity end-date content is provided here. Timelines require authoritative FDA exclusivity and Orange Book patent expiration dates for Estrostep FE and each listed dosage form/strength.

What patent litigation affects Estrostep FE generic entry risk?

No litigation status is provided here. Mapping Paragraph IV disputes, settlements, and case outcomes requires docket-specific data tied to Estrostep FE’s Orange Book patents.

What generic entry risks exist for Estrostep FE?

Generic entry risk in CHCs is high once AB-rated alternatives are available and when payer formularies shift preference to lowest net-cost options. For Estrostep FE, the practical risks are:

• Formulary switching: Even after a brand retains “covered” status, preferred-tier placement can shift to generics.
• Copay dynamics: If generic copays are lower, adherence shifts toward lower-cost options.
• Pack-size and contracting: PBMs often contract by pack size and reimbursement rates, driving substitution.

Featured snippet takeaway: The main near- to mid-term financial risk is formulary preference loss, which typically precedes or accelerates unit and pricing declines.

How do formulation patents and method-of-use claims impact Estrostep FE competition?

No formulation- or method-of-use patent mapping is provided here. Determining whether competitors face barriers on formulation process, iron tablet components, or clinical labeling requires a patent estate review tied to the specific Estrostep FE NDA listing.

How strong is the patent estate for Estrostep FE compared with other oral contraceptives?

No patent-estate strength assessment is provided here. A comparative strength view requires specific patent counts, jurisdictions, remaining term, claim scope, and enforcement history across relevant CHC products.

What FDA status milestones shape Estrostep FE commercialization?

Estrostep FE’s FDA status is not provided here. A commercialization timeline depends on:

• NDA approval date and labeling versions
• Supplement history relevant to manufacturing or formulation changes
• Current status (e.g., active marketing, discontinued statuses, or withdrawals)
• Any changes affecting substitutability and PBM contracting

How does Estrostep FE make money: pricing, rebates, and payer behavior?

CHCs monetize through a blend of:

• Wholesale acquisition cost (WAC) setting and negotiated discounts
• Rebates and fees tied to formulary performance and volume
• PBM spread management and step therapy policies
• Patient assistance and copay support (where used to preserve adherence)

Financial trajectory pattern in CHCs

• As generics enter, branded products often respond via:
  • Increased net price concessions
  • More reliance on contracted lives
  • Reduced gross-margin footprint

What is the revenue exposure for Estrostep FE under different generic launch scenarios?

No unit, revenue, or market-share figures are provided here. Scenario modeling requires at minimum:

• Historical prescription volume by channel
• Net pricing versus gross WAC
• Formulary share and tier placement over time
• Generic penetration timing by strength/pack
• Claims and rebates estimates

Key Takeaways

• Estrostep FE’s financial trajectory in a mature CHC market is driven primarily by formulary access and net pricing erosion after generic/AB-rated alternatives appear.
• Exclusivity and patent coverage typically determine the timing of revenue decline, not the end-state, in oral contraceptives.
• Competitive pressure in CHCs is structurally high because many products are therapeutically substitutable, and payer contracting favors the lowest net-cost option.
• A defensible investment or litigation view requires a complete Orange Book and litigation mapping, which is not included in the provided context.

FAQs

1. How do PBM formulary tiers typically affect branded oral contraceptives’ net sales after generic launches?
2. What determines whether patients switch away from one combined hormonal contraceptive to another when generics are available?
3. How do settlement agreements in CHC Paragraph IV cases usually influence launch timing and brand revenue pacing?
4. Do iron-containing “FE” placebo weeks affect interchangeability or payer substitution behavior for Estrostep FE?
5. What manufacturing and packaging issues most often drive differentiation or regulatory friction in generic oral contraceptives?

References

None provided in the prompt.